Moleac's largest ever clinical trial on stroke recovery medication
NeuroAid(TM), a traditional Chinese medicine (TCM) to aid stroke recovery, is set to undergo the largest clinical trial ever conducted on a stroke recovery medication. The trial targets stroke patients, who will be recruited within 48 hours of stroke incidence at participating hospitals.
The study will be carried out by the CHIMES Society, which aims to study the efficacy of NeuroAidTM on stroke recovery at acute stage. Members include renowned neurologists from Europe and Asia. This trial will roll out progressively at several hospitals beginning in Singapore in October 2007.
The CHIMES Stroke Study is ground-breaking for the medical industry as the largest clinical trial on stroke recovery and the first time any TCM product has been assessed on this wide a scale outside China. The two-year study is a unique collaboration between stroke centres across South-East Asia, including the University of Santo Tomas hospital in the Philippines, and a number of leading hospitals in Thailand.
In Singapore the study is supported by a grant from the National Medical Research Council (NRMC).
David Picard, CEO of Moleac, the Singapore-based biopharmaceutical company that develops and markets NeuroAidTM outside of China, said, "We are delighted at the interest NeuroAidTM has generated among the medical community worldwide. Over 200,000 patients in China are using NeuroAidTM every year, and we get positive feedback from individual patients internationally. Nevertheless we still need to generate accepted Western data from the early stages of stroke to further validate its use, and to encourage the international medical community at large to prescribe it to their patients."
Other news from the department research and development
